7BG0 Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and immune-evasive in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
BerGenBio ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.12 |
| 52 Week High | NOK 1.26 |
| 52 Week Low | NOK 0.079 |
| Beta | 1.18 |
| 1 Month Change | 18.99% |
| 3 Month Change | -80.27% |
| 1 Year Change | -87.73% |
| 3 Year Change | -99.92% |
| 5 Year Change | -99.97% |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7BG0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 16.6% | -1.4% | -0.9% |
| 1Y | -87.7% | -12.5% | 14.1% |
Return vs Industry: 7BG0 underperformed the German Biotechs industry which returned -12.5% over the past year.
Return vs Market: 7BG0 underperformed the German Market which returned 14.1% over the past year.
Price Volatility
| 7BG0 volatility | |
|---|---|
| 7BG0 Average Weekly Movement | 40.0% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 7BG0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7BG0's weekly volatility has increased from 25% to 40% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 13 | Olav Hellebo | www.bergenbio.com |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and immune-evasive in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and BGBIL025, a JAK2 inhibitor, which is in preclinical stage for treatment of the bone marrow disorder myelofibrosis. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.
BerGenBio ASA Fundamentals Summary
| 7BG0 fundamental statistics | |
|---|---|
| Market cap | €6.56m |
| Earnings (TTM) | -€12.15m |
| Revenue (TTM) | €73.96k |
Is 7BG0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7BG0 income statement (TTM) | |
|---|---|
| Revenue | NOK 848.00k |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 848.00k |
| Other Expenses | NOK 140.13m |
| Earnings | -NOK 139.28m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Aug 20, 2025
| Earnings per share (EPS) | -3.56 |
| Gross Margin | 100.00% |
| Net Profit Margin | -16,424.76% |
| Debt/Equity Ratio | 0.7% |
How did 7BG0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/24 07:36 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BerGenBio ASA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ulrik Trattner | Carnegie Investment Bank AB |
| Geir Holom | DNB Markets |
| Sean Conroy | Edison Investment Research |